Form 4: Janux Therapeutics Director Receives Shares via Pro Rata Distribution
SEC Form 4 Filing
Sheila Gujrathi, a director at Janux Therapeutics, received 4,611 shares of common stock through a pro rata, in-kind distribution on November 5, 2024.
Summary
- Sheila Gujrathi, a director of Janux Therapeutics, Inc. [JANX], reported a change in beneficial ownership of the company's common stock on November 5, 2024.
- The transaction involved the acquisition of 4,611 shares of common stock through a pro rata, in-kind distribution.
- Gujrathi's beneficial ownership following the transaction is 115,139 shares.
- The shares were received as a distribution from ABV SPV I GP LLC, of which Gujrathi is a member, and not as a purchase.
- The report was filed on November 7, 2024.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 11/05/2024 | Date of transaction: Sheila Gujrathi acquired 4,611 shares of Janux Therapeutics common stock through a pro rata, in-kind distribution. |
| 11/07/2024 | Date of report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.